This is a randomized double blind placebo-controlled clinical trial to evaluate the effect of l-carnitine on sleep quality of 56 hemodialysis patients in Emam Khomeini hospital of Shirvan. Inclusion criteria: Signing informed consent, Being on hemodialysis three times a week for at least 6 months prior to the study, age over 18. Exclusion criteria: Refusal at any time to continue the study, History of l-carnitine , vit c and vit E consumption, History of transquilizers, hypnotics or sedatives consumption, History of severe neuropsychology, cardiac, respiratory, liver disease, History of renal transplantation. After approving of the study by sciences vice chancellor of Sabzevar University of Medical Sciences and completing of written consent form by all participants in the study, Patients will be divided randomly into two equal groups. Intervention group will receive 500mg l-carnitine orally twice a day for 12 weeks and control group will receive placebo for 12 weeks. Also, the patients is asked during the study period, not to have any changes in medications, diet and exercise. At the beginning and end of the study, the Pittsburgh sleep quality index (PSQI) questionnaire will be completed by the patients to measure quality and sleep patterns.